After First-Line Chemotherapy for Good-Prognosis Metastatic NSGCT: Managing Residual Retroperitoneal Disease

In patients with non-seminomatous germ cell tumour (NSGCT) classified as IGCCCG good prognosis, standard first-line chemotherapy is the initial step. When residual retroperitoneal masses remain after that chemotherapy, a structured surgical protocol defines what comes next.

Previous Treatment & Escalation Trigger

First-line therapy in this setting consists of BEP ×3 (cisplatin, etoposide, bleomycin for 3 cycles at 21-day intervals) or, when bleomycin is clearly contraindicated, EP ×4 (etoposide, cisplatin for 4 cycles).

The goals of that line are normalisation of serum tumour markers (AFP, hCG, LDH) and complete or partial radiological response on cross-sectional imaging. When visible residual retroperitoneal masses persist after chemotherapy — even with markers normalising — this protocol defines the required next step.

IGCCCG Good Prognosis — Defining Criteria

This protocol applies when all of the following are present:

Testis or retroperitoneal primary tumour
No nonpulmonary visceral metastases
AFP < 1,000 ng/mL
hCG < 5,000 IU/L
LDH < 1.5 × upper limit of normal

Approach (Partial Overview)

The protocol involves a nerve-sparing surgical approach to visible residual retroperitoneal disease. Patient selection, procedural scope, and sequencing details are defined in the full structured regimen.

Complete algorithm, eligibility thresholds, and procedural specifics are available below.

Clinical Goals

The target outcome is complete resection of residual masses, with histological assessment of the specimen. Tissue may represent necrotic-fibrotic material, postpubertal teratoma, or active cancer — a distinction that directly guides further management decisions.

Instant Access to Structured Evidence-Based Regimens

References

All of the following criteria: Testis/retroperitoneal primary, No nonpulmonary visceral metastases, AFP < 1,000 ng/mL, hCG < 5,000 IU/L (1,000 ng/mL), LDH < 1.5 x ULN.

Perform surgical resection of visible (> 1 cm in longest diameter) residual masses after chemotherapy for NSGCT when serum levels of tumour markers are normal or normalising.

When resection is indicated, bilateral nerve-sparing RPLND is the standard option.

Following first-line BEP it has been reported that about 7% of residual masses contain active cancer, 33% postpubertal teratoma, and 40% necrotic-fibrotic tissue only.

View source ↗